Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

119.39
6,741,790

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Abbott (ABT) Makes Progress in the TAVI Space With Navitor

Results from Abbott's (ABT) PORTICO study support Navitor's recent FDA approval to treat patients with severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Abbott's (ABT) MitraClip Device Shows Favorable Outcome

Abbott's (ABT) landmark COAPT trial demonstrated that MitraClip is safe and effective and can reduce the hospitalization rate.

Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?

Style Box ETF report for DEF

Should You Invest in Abbott (ABT) Based on Bullish Wall Street Views?

According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

Abbott (ABT) closed the most recent trading day at $102.63, moving +1.79% from the previous trading session.

Abbott (ABT) Dips More Than Broader Markets: What You Should Know

Abbott (ABT) closed the most recent trading day at $100.83, moving -0.87% from the previous trading session.

Why Is Abbott (ABT) Down 7.7% Since Last Earnings Report?

Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Abbott (ABT) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Abbott (ABT) closed at $102.55, marking a -0.14% move from the previous day.

Here's Why You Should Retain Abbott (ABT) Stock for Now

Investors are optimistic about Abbott (ABT) owing to continued growth in the Diabetes business.

Abbott (ABT) to Expand Vascular Device Line With New Buyout

Abbott's (ABT) latest deal will help gain access to Cardiovascular System's leading atherectomy device to treat vascular disease.

Abbott (ABT) EPD Growth Continues Amid Macroeconomic Challenges

At Abbott (ABT), Medical Device sales growth is led by strong performance in Electrophysiology, Structural Heart and Diabetes Care.

The Zacks Analyst Blog Highlights Abbott Laboratories, Boeing, Diageo, Lam Research and Freeport-McMoRan

Abbott Laboratories, Boeing, Diageo, Lam Research and Freeport-McMoRan are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Abbott Laboratories, Boeing & Diageo

Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), The Boeing Company (BA) and Diageo plc (DEO).

Urmimala Biswas headshot

3 MedTech Stocks Likely to Beat Estimates This Earnings Season

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.

Ensign Group (ENSG) Shares Down 2% Since Q4 Earnings Release

Ensign Group's (ENSG) fourth-quarter results indicate higher skilled services revenue and improved occupancies, partly offset by the increased cost of services.

Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?

Smart Beta ETF report for NOBL

Humana (HUM) Q4 Earnings Beat Mark, '23 EPS View Upbeat

Humana's (HUM) fourth-quarter results benefit from solid premiums from its individual Medicare Advantage business and the sound performance of the two newly formed segments.

ZBH vs. ABT: Which Stock Is the Better Value Option?

ZBH vs. ABT: Which Stock Is the Better Value Option?

Abbott (ABT) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Abbott's (ABT) Q4 Earnings Beat Estimates, Margins Down

The downside can be attributed to a manufacturing disruption during 2022 of certain infant formula products at Abbott's (ABT) Sturgis, MI facility.

Pre-Markets Edge Lower With Q4 Earnings Underway

Pre-Markets Edge Lower With Q4 Earnings Underway

Mark Vickery headshot

Pre-Markets Sink on Quarterly Earnings Ruminations

Between Microsoft's deceleration in its Azure cloud business and Boeing's huge bottom-line miss, we start the day with challenges ahead.

Abbott (ABT) Q4 Earnings and Revenues Top Estimates

Abbott (ABT) delivered earnings and revenue surprises of 14.44% and 6.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Abbott's (ABT) New FDA Approval to Improve Patient Outcome

Abbott's (ABT) latest regulatory clearance is expected to improve the treatment of high-risk patients with aortic stenosis.

Surmodics (SRDX) Stock Skids 32% on Negative Regulatory Update

Surmodics' (SRDX) SurVeil drug-coated balloon candidate receives additional data requests from the FDA.